Cancer Investigation最新文献

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis. 黑色素瘤合并多发性原发恶性肿瘤的临床特征及对预后的影响：回顾性分析。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-05-23 DOI: 10.1080/07357907.2025.2507113

Huichun Tian, Jiaran Zhang, Lili Mao, Caili Li, Xiaoting Wei, Junjie Gu, Li Zhou, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Jun Guo, Lu Si

{"title":"Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.","authors":"Huichun Tian, Jiaran Zhang, Lili Mao, Caili Li, Xiaoting Wei, Junjie Gu, Li Zhou, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Jun Guo, Lu Si","doi":"10.1080/07357907.2025.2507113","DOIUrl":"https://doi.org/10.1080/07357907.2025.2507113","url":null,"abstract":"Introduction: This study aims to explore the clinical characteristics and prognosis of patients with melanoma (MM), which are composed mainly of acral and mucosal MM accompanied by multiple primary tumors.Methods: A total of 87 patients diagnosed with single primary MM and 87 patients diagnosed with multiple primary malignant tumors were included. Nonmelanoma malignancy tumor type, genetic testing, and the survival data were collected. Pearson's chi-square test, Fisher's exact test, log-rank test, univariate and multivariate Cox's regression analysis were applied.Results: The most common nonmelanoma malignancies in all patients involved the digestive system; breast cancer, thyroid cancer, lung cancer, and prostate cancer; and breast cancer was more common in patients with acral MM. Mutations in BRAF V600, NRAS, KIT, and TP53 were the most common. Univariate analysis revealed that mutations in KIT and elevated levels of lactate dehydrogenase (LDH) were potential factors that influenced OS. Multivariate analysis revealed that mutations in NRAS and increased LDH levels were related to worse survival and that survival was prolonged in patients with MM as the first primary tumor.Conclusion: This study preliminarily describes the clinical features and prognosis of patients with melanomas, while the further study with larger sample size is needed.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis. 晚期尿路上皮癌患者接受维多汀治疗时高血糖风险增加：一项系统回顾和荟萃分析

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-05-13 DOI: 10.1080/07357907.2025.2502992

Ryan Cheng, Montek Boparai, Xiaolei Zhu, Shenhong Wu

{"title":"Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.","authors":"Ryan Cheng, Montek Boparai, Xiaolei Zhu, Shenhong Wu","doi":"10.1080/07357907.2025.2502992","DOIUrl":"https://doi.org/10.1080/07357907.2025.2502992","url":null,"abstract":"Background: Enfortumab vedotin, an anti-nectin-4 antibody-drug conjugate, is a key treatment for advanced urothelial cancer. However, hyperglycemia, a major adverse event, varies in incidence and can progress to diabetic ketoacidosis. We conducted a systematic review and meta-analysis to quantify the risk of hyperglycemia with enfortumab vedotin.Material and methods: We searched studies published through September 30, 2024. Eligible clinical trials evaluated enfortumab vedotin as a monotherapy or combined with pembrolizumab. Pooled incidence and relative risk of hyperglycemia were calculated using random- or fixed-effects models.Results: Seven studies with 2,138 patients were included in our analysis. The summary incidence of all-grade hyperglycemia was 10.3% (95% CI: 8.6-12.2%), and high-grade hyperglycemia occurred in 5.7% (95% CI: 4.5-7.1%) of patients. No significant difference was observed between monotherapy and combination therapy (p = 0.16). Enfortumab vedotin significantly increased the risk of all-grade (RR = 16.97, 95% CI: 6.22-48.25, p < 0.001) and high-grade hyperglycemia (RR = 34.78, 95% CI: 4.77-253.43, p < 0.001).Conclusion: Enfortumab vedotin is associated with a significantly increased risk of all-grade and high-grade hyperglycemia in urothelial cancer. Its combination with pembrolizumab does not appear to elevate this risk further. Routine glucose monitoring and early intervention should be implemented, particularly in high-risk patients.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Association Between Vulnerability and Taste Changes in Older Cancer Patients Undergoing Chemotherapy. 接受化疗的老年癌症患者的脆弱性和味觉变化之间的关系。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-05-05 DOI: 10.1080/07357907.2025.2500495

Yajun Dong, Jiajia Lu, Danhui Wang, Min Zhu, Liping Teng

{"title":"The Association Between Vulnerability and Taste Changes in Older Cancer Patients Undergoing Chemotherapy.","authors":"Yajun Dong, Jiajia Lu, Danhui Wang, Min Zhu, Liping Teng","doi":"10.1080/07357907.2025.2500495","DOIUrl":"https://doi.org/10.1080/07357907.2025.2500495","url":null,"abstract":"This study aimed to examine the association between taste changes and vulnerability in elderly cancer patients undergoing chemotherapy. A cross-sectional study was conducted among older cancer patients undergoing chemotherapy in Wuxi, China. The Chemotherapy-induced Taste Alteration Scale (CiTAS) was used to measure taste alteration. The Vulnerable Elders Survey (VES) was used to measure vulnerability status. The univariate, correlation, and hierarchical regression analyses were applied to assess the association between taste changes and vulnerability. Of 200 older cancer patients, 123 (61.5%) participants were non-vulnerable. The univariate analysis revealed significant distribution differences of vulnerability in education level, smell abnormalities, drinking history, chemotherapy cycle, and taste changes. The level of taste changes was positively correlated with vulnerability (r = 0.401, p < 0.01). Results of the regression analysis indicated that vulnerability in older cancer patients was significantly associated with higher odds of \"phantogeusia and parageusia\" (OR = 4.505, p < 0.001). Taste changes may be an important influencing factor of vulnerability in older cancer patients.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Impedance Cardiography for Detection of Early Cardiac Effects of Radiotherapy in Breast Cancer Patients. 应用阻抗心动图检测乳腺癌放疗对心脏的早期影响。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.1080/07357907.2025.2498360

Hilmi Ugras, Belgin Buyukakilli, Songul Barlaz Us, Eda Bengi Yilmaz, Cagatay Han Turkseven

{"title":"The Use of Impedance Cardiography for Detection of Early Cardiac Effects of Radiotherapy in Breast Cancer Patients.","authors":"Hilmi Ugras, Belgin Buyukakilli, Songul Barlaz Us, Eda Bengi Yilmaz, Cagatay Han Turkseven","doi":"10.1080/07357907.2025.2498360","DOIUrl":"10.1080/07357907.2025.2498360","url":null,"abstract":"This study was conducted to determine the effect of radiotherapy (RT) on heart functions in the early period in patients with breast cancer. The hemodynamic parameters showing heart functions of patients were recorded by impedance cardiography (ICG), a noninvasive method for monitoring heart function before and after RT. Some hemodynamic parameters of patients compared to before RT increased significantly after RT. Hemodynamic parameters that increased significantly following RT, compared with baseline: cardiac index (CI) (l/min/m2), before radiotherapy 3.21 ± 0.71, after radiotherapy 3.75 ± 1.01; stroke volume index (SVI) (ml/min/m2), before radiotherapy 37.32 ± 8.87, after radiotherapy 44.49 ± 10.85; thoracic fluid volume (TFC) (kohm-1), before radiotherapy 35.43 ± 7.70, after radiotherapy 39.52 ± 10.37. The findings suggested that short-term effects of RT on hemodynamic parameters in breast cancer patients were not due to deterioration in heart functions, but could be due to radiodermatitis, which can be seen in patients up to 42 days after RT. As a part of the treatment plan of patients receiving RT, it may be recommended to determine changes in heart functions with ICG and to plan new studies in which patients will be followed for a longer period.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"267-281"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Impression Cytology for Diagnosis of Ocular Surface Squamous Neoplasia in Two Kenyan Tertiary Hospitals. 肯尼亚两所三级医院印象细胞学诊断眼表鳞状瘤变的评价。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-15 DOI: 10.1080/07357907.2025.2492031

Chisomo Griffin Phiri, Rhoda M Munene, Stephen Gichuhi, Lucy W Muchiri

{"title":"Evaluation of Impression Cytology for Diagnosis of Ocular Surface Squamous Neoplasia in Two Kenyan Tertiary Hospitals.","authors":"Chisomo Griffin Phiri, Rhoda M Munene, Stephen Gichuhi, Lucy W Muchiri","doi":"10.1080/07357907.2025.2492031","DOIUrl":"10.1080/07357907.2025.2492031","url":null,"abstract":"Introduction: Ocular surface squamous neoplasia (OSSN) is a broad term encompassing pre-cancerous and cancerous conditions affecting the ocular surface. Given the non-specific clinical presentation, there is a need for reliable diagnostic tools that can be used in resource-limited settings. This study assessed the diagnostic accuracy of Impression Cytology (IC) in diagnosing OSSN, compared to histopathology, the gold standard.Methods: A diagnostic accuracy study was conducted involving 40 patients suspected to have OSSN at Kenyatta National Hospital and Kikuyu Hospital. Patients were scheduled for IC followed by surgical excision and Histopathological examination. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated.Results: There were 40 participants, 28 females and 12 males, with a mean age of 40.5 years (range 18-70). IC had a sensitivity of 100%, specificity of 82.1%, accuracy of 87.5%, positive predictive value of 70.6%, and negative predictive value of 100%.Conclusion: IC is an effective, minimally invasive diagnostic tool for OSSN, demonstrating high sensitivity and negative predictive value. Its implementation in clinical settings could improve early detection and management of OSSN, particularly in regions with limited access to histopathological services.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"237-243"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy. 卡培他滨增强近距离治疗局部晚期宫颈癌：安全性和有效性的II期非随机试验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-23 DOI: 10.1080/07357907.2025.2493238

Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Indira Prasad Giri, Seyed Alireza Javadinia, Mahdiye Dayanni, Habibollah Esmaily, Maliheh Hasanzadeh Mofard

{"title":"Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy.","authors":"Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Indira Prasad Giri, Seyed Alireza Javadinia, Mahdiye Dayanni, Habibollah Esmaily, Maliheh Hasanzadeh Mofard","doi":"10.1080/07357907.2025.2493238","DOIUrl":"10.1080/07357907.2025.2493238","url":null,"abstract":"Aim: To evaluate the safety and efficacy of administering capecitabine concurrent with brachytherapy in advanced-stage cervical cancer.Methods: Eligible patients with FIGO stage IB2-IVA cervical cancer were enrolled in this phase II non-randomized trial. After external beam chemoradiotherapy (EBRT), patients received capecitabine alongside brachytherapy as radiosensitizer. The primary objective was to assess the tolerability of the combined regimen and its effect on one-year disease-free (DFS) and overall survival rates (OS).Results: Of the 69 patients completed treatment, 18 were enrolled as intervention group and 51 served as controls. Both groups were matched in terms of comorbidities, stage, and response to EBRT. Overall, concurrent capecitabine administration during brachytherapy was safe. At one-year follow-up, one death was recorded in each group, with recurrence rates of 16.7% in the intervention group and 19.6% in the control group. One-year DFS was 82% (95% CI: 54%-98%) in the intervention group and 87% (95% CI: 72%-94%) in the control group, while one-year OS was 93% (95% CI: 53%-98%) and 97% (95% CI: 85%-99%), respectively (for both p < 0.05).Conclusion: In conclusion, while capecitabine-augmented brachytherapy was demonstrated to be safe in patients with advanced cervical cancer, its addition did not yield significant improvements in DFS or OS.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"244-256"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience. 硬纤维瘤病的临床挑战和不断发展的治疗：单一机构的经验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-21 DOI: 10.1080/07357907.2025.2493240

Austin Yu, Zachary Butler, Lesly Honore, Gabrielle Unson, Matthew Demetrious, Steven Gitelis, Jordan Tasse, Alan T Blank

{"title":"Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.","authors":"Austin Yu, Zachary Butler, Lesly Honore, Gabrielle Unson, Matthew Demetrious, Steven Gitelis, Jordan Tasse, Alan T Blank","doi":"10.1080/07357907.2025.2493240","DOIUrl":"10.1080/07357907.2025.2493240","url":null,"abstract":"Desmoid tumor (DT), also known as desmoid fibromatosis, is a rare, locally proliferative tumor characterized by an overgrowth of myofibroblastic cells. Due to the varied clinical presentation of DT, there are a multitude of treatment options. This study provides our institutional experience in characterizing and treating DT as well as patient outcomes. A retrospective review was performed for 49 patients diagnosed with DT. Patient demographics, tumor characteristics, treatment characteristics, and tumor recurrence were reported. We reported our institution's treatment trends over time, relative risk analysis for surgery, as well as univariate analysis for recurrence. Thirty-seven patients received surgery with an overall recurrence rate of 29.7% (11/37). In total, ten patients received medical therapy including tamoxifen/sulindac (n = 7), nirogacestat (n = 1), and sorafenib (n = 2). One patient has been followed with active surveillance. Relative risk for surgery and tumor recurrence was not significantly correlated with race, gender, location, or large tumor size > 5 cm. Four patients treated with medical therapy experienced tumor reduction and symptomatic improvement. Management of DT includes many surgical and non-surgical options. We noted a similar recurrence rate in patients who received surgical treatment to what has been reported in the literature roughly 33%. We also noted effective tumor control in patients receiving medical therapy. As such, surgery can be utilized in situations with well-demarcated DT which can be removed en bloc, while utilizing medical therapy for highly invasive tumors.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"257-266"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Colon Cancer Prediction from Histopathological Images Using Enhanced Deep Learning with Confidence Scoring. 使用增强深度学习和信心评分从组织病理学图像中预测早期结肠癌。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-04-03 DOI: 10.1080/07357907.2025.2483302

V P Gladis Pushparathi, J Shajeena, T Kamalam, M Revathi

{"title":"Early Colon Cancer Prediction from Histopathological Images Using Enhanced Deep Learning with Confidence Scoring.","authors":"V P Gladis Pushparathi, J Shajeena, T Kamalam, M Revathi","doi":"10.1080/07357907.2025.2483302","DOIUrl":"10.1080/07357907.2025.2483302","url":null,"abstract":"Colon Cancer (CC) arises from abnormal cell growth in the colon, which severely impacts a person's health and quality of life. Detecting CC through histopathological images for early diagnosis offers substantial benefits in medical diagnostics. This study proposes NalexNet, a hybrid deep-learning classifier, to enhance classification accuracy and computational efficiency. The research methodology involves Vahadane stain normalization for preprocessing and Watershed segmentation for accurate tissue separation. The Teamwork Optimization Algorithm (TOA) is employed for optimal feature selection to reduce redundancy and improve classification performance. Furthermore, the NalexNet model is structured with convolutional layers and normal and reduction cells, ensuring efficient feature representation and high classification accuracy. Experimental results demonstrate that the proposed model achieves a precision of 99.9% and an accuracy of 99.5%, significantly outperforming existing models. This study contributes to the development of an automated and computationally efficient CC classification system, which has the potential for real-world clinical implementation, aiding pathologists in early and accurate diagnosis.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"205-223"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer. 自然产生的生物活性阿片生长因子在不可切除肝细胞癌患者中的I期研究

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-04-08 DOI: 10.1080/07357907.2025.2484774

Eric T Kimchi, Jussuf T Kaifi, Yixing Jiang, Guangfu Li, Diego M Avella, Niraj J Gusani, Ian Schreibman, Peter Waybill, Patricia J McLaughlin, Ian S Zagon, Jill P Smith, Kevin F Staveley-O'Carroll

{"title":"A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer.","authors":"Eric T Kimchi, Jussuf T Kaifi, Yixing Jiang, Guangfu Li, Diego M Avella, Niraj J Gusani, Ian Schreibman, Peter Waybill, Patricia J McLaughlin, Ian S Zagon, Jill P Smith, Kevin F Staveley-O'Carroll","doi":"10.1080/07357907.2025.2484774","DOIUrl":"10.1080/07357907.2025.2484774","url":null,"abstract":"Hepatocellular cancer (HCC), one of the world's most deadly tumors, and its incidence in the US continues to rise. Surgical resection/transplantation offers the only hope for cure; however, many patients are not candidates and have limited therapeutic options. Opioid growth factor (OGF) is a naturally occurring bioactive endogenous pentapeptide that inhibits growth of human HCC cell lines in vitro by a receptor-mediated mechanism and inhibits progression of tumors in nude mice. Based on these preclinical studies, we conducted a phase I clinical trial with dose escalation (standard 3 + 3 protocol) of OGF to determine the maximum tolerated dose in HCC patients with concomitant liver disease (NCT00706576). Fifteen doses were administered to 14 patients with a maximum 300 µg/kg dose. No Grade 3 toxicities were encountered in the study group. This dose exceeds the maximum tolerated dose reached in our previous phase I pancreatic cancer trial. We conclude that OGF can be safely administered to patients with HCC and concomitant liver disease without significant toxicities up to a dose of 300 µg/kg. The result of this trial provides data on toxicity and the pharmacokinetics of OGF in patients with HCC and liver disease and lays the groundwork for additional studies.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"224-235"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial. 局部姜黄素预防辐射性皮炎：一项双盲安慰剂对照试验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-03-27 DOI: 10.1080/07357907.2025.2479542

Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi

{"title":"Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial.","authors":"Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi","doi":"10.1080/07357907.2025.2479542","DOIUrl":"10.1080/07357907.2025.2479542","url":null,"abstract":"Background: Radiation-induced dermatitis, a common radiotherapy (RT) complication, affects 95% of breast cancer patients, with 10% experiencing severe reactions. Despite advancements, radiation dermatitis remains a challenge, disrupting treatment schedules and compromising patients' quality of life. Exploring herbal compounds, particularly Curcumin, has shown promise in addressing radiation-induced dermatitis, with its non-toxic and anti-inflammatory properties offering the potential for clinical trials to prevent these reactions.Methods: This phase II randomized, double-blinded, placebo-controlled trial focused on adult females undergoing conventional fractionated RT. The main objective was to assess the efficacy of topical Curcumin in reducing the severity of radiation dermatitis.Results: During a five-month study, 52 breast cancer patients completed the research. Participants were divided into Curcumin and placebo groups. In the first week, a significant difference in redness (P-value = 0.001) and irritation (P-value = 0.017) was observed, with the Curcumin group showing lower percentages. This trend continued in the second, third, and fourth weeks (P-value = 0.001). No statistical difference was found in itching (P-value = 0.446), and the occurrence of dryness (P-value = 1.000) remained constant in both groups throughout the four weeks. In pain the differences were significant in the second, third, and fourth weeks (P-value = 0.001).Conclusion: The study highlights the success of a 2% Curcumin gel in reducing skin side effects during breast cancer radiation therapy, suggesting its potential to enhance patients' quality of life.Trial registration: IRCT20181208041882N3, 06/11/2020 (https://en.irct.ir/trial/49228).","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"173-182"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0